Processa Pharmaceuticals, Inc. Financing Receivable, after Allowance for Credit Loss
Processa Pharmaceuticals, Inc. (PCSA) had Financing Receivable, after Allowance for Credit Loss of $88.76 thousand as of 2015-06-30, per its 10-Q filed 2015-08-19.
Discontinued › Balance Sheet › Assets
us-gaap:NotesReceivableNet · last filed 2015-08-19
- 2015-06-30: Financing Receivable, after Allowance for Credit Loss $88.76K.
- 2015-03-31: Financing Receivable, after Allowance for Credit Loss $86.21K.
| Period end | Financing Receivable, after Allowance for Credit Loss |
|---|---|
| 2015-06-30 | $88.76K 10-Q · filed 2015-08-19 |
| 2015-03-31 | $86.21K 10-Q · filed 2015-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |